公开(公告)号：US20210046074A1

公开(公告)日：2021-02-18

申请号：US16910921

申请日：2020-06-24

Applicant: eFFECTOR Therapeutics, Inc.

Inventor： Kevin R. Webster ,  Vikas Goel

IPC: A61K31/506 ,  A61K39/395 ,  A61K31/713 ,  A61K45/06

Abstract: The present disclosure relates to the use MNK-specific inhibitors to inhibit immunosuppression components, such as immune checkpoint proteins PD-1, PD-L1, LAG3, and/or immunosuppressive cytokines, such as IL-10, in order to inhibit or release immune suppression in certain diseases, such as cancer and infectious disease.

公开(公告)号：US10780119B2

公开(公告)日：2020-09-22

申请号：US15989098

申请日：2018-05-24

Applicant: eFFECTOR Therapeutics, Inc.

Inventor： Kevin R. Webster ,  Rajesh Sharma ,  Gary Chiang

IPC: A61K48/00 ,  C07H21/02 ,  C07H21/04 ,  A61K35/17 ,  C07K14/74 ,  A61P35/00 ,  C07K14/725 ,  C07K14/73 ,  C07K14/16 ,  C07K14/705 ,  C12N5/0783 ,  C07D471/04 ,  C07D487/04 ,  C07D495/20 ,  C07D491/20 ,  C07D471/20 ,  A61K31/501 ,  A61K45/06

Abstract: The present disclosure relates to genetically modified T cells comprising a transgene encoding an engineered antigen specific receptor, wherein expression of an endogenous gene selected from MNK1, MNK2, or both are inhibited in the genetically modified T cell in order to enhance central memory T cell subsets in cellular immunotherapy compositions.

公开(公告)号：US10702526B2

公开(公告)日：2020-07-07

申请号：US15130538

申请日：2016-04-15

Applicant: eFFECTOR Therapeutics, Inc.

Inventor： Kevin R. Webster ,  Vikas Goel

IPC: A61K31/519 ,  A61K31/52 ,  A61K31/506 ,  A61K39/395 ,  A61K31/713 ,  A61K45/06 ,  A61K39/00

Abstract: The present disclosure relates to the use MNK-specific inhibitors to inhibit immunosuppression components, such as immune checkpoint proteins PD-1, PD-L1, LAG3, and/or immunosuppressive cytokines, such as IL-10, in order to inhibit or release immune suppression in certain diseases, such as cancer and infectious disease.

公开(公告)号：US20160303124A1

公开(公告)日：2016-10-20

申请号：US15130538

申请日：2016-04-15

Applicant: eFFECTOR Therapeutics, Inc.

Inventor： Kevin R. Webster ,  Vikas Goel

IPC: A61K31/506 ,  A61K31/713 ,  A61K45/06 ,  A61K39/395

Abstract: The present disclosure relates to the use MNK-specific inhibitors to inhibit immunosuppression components, such as immune checkpoint proteins PD-1, PD-L1, LAG3, and/or immunosuppressive cytokines, such as IL-10, in order to inhibit or release immune suppression in certain diseases, such as cancer and infectious disease.

Abstract translation: 本公开涉及使用MNK特异性抑制剂来抑制免疫抑制成分，例如免疫检查点蛋白质PD-1，PD-L1，LAG3和/或免疫抑制性细胞因子如IL-10，以便抑制或释放免疫 抑制某些疾病，如癌症和传染病。

公开(公告)号：US11576933B2

公开(公告)日：2023-02-14

申请号：US16616087

申请日：2018-05-24

Applicant: EFFECTOR THERAPEUTICS, INC.

Inventor： Peggy A. Thompson ,  Kevin R. Webster

IPC: A61K35/17 ,  A61P35/00 ,  A61K31/343 ,  A61K31/4355 ,  A61K45/06 ,  C07D471/12

Abstract: The present disclosure provides compositions and methods for improving an antitumor response against non-inflamed solid tumors. Methods of this disclosure include use of an eIF4A inhibitor to promote infiltration of antitumor lymphocytes into a non inflamed solid tumor. Methods of treating cancer associated with a non-inflamed solid tumor are also provided.

公开(公告)号：US11564947B2

公开(公告)日：2023-01-31

申请号：US17025607

申请日：2020-09-18

Applicant: eFFECTOR Therapeutics, Inc.

Inventor： Kevin R. Webster ,  Rajesh Sharma ,  Gary Chiang

IPC: C07H21/04 ,  A61K35/17 ,  C07K14/74 ,  A61P35/00 ,  C07K14/725 ,  C07K14/73 ,  C07K14/16 ,  C07K14/705 ,  C12N5/0783 ,  C07D471/04 ,  C07D487/04 ,  C07D495/20 ,  C07D491/20 ,  C07D471/20 ,  A61K31/501 ,  A61K45/06

Abstract: The present disclosure relates to genetically modified T cells comprising a transgene encoding an engineered antigen specific receptor, wherein expression of an endogenous gene selected from MNK1, MNK2, or both are inhibited in the genetically modified T cell in order to enhance central memory T cell subsets in cellular immunotherapy compositions.

公开(公告)号：US20210299111A1

公开(公告)日：2021-09-30

申请号：US17210062

申请日：2021-03-23

Applicant: eFFECTOR Therapeutics Inc.

Inventor： Peggy A. Thompson ,  Kevin R. Webster

IPC: A61K31/4355 ,  A61K9/00 ,  A61K45/06 ,  A61P35/04

Abstract: The present disclosure relates to methods for ameliorating or treating an eIF4A dependent condition or disease in a subject in need thereof. The methods of the disclosure comprise administering to the subject a therapeutically effective amount of at least one eukaryotic translation initiation factor 4A (eIF4A) inhibitor and a therapeutically effective amount of at least one cyclin-dependent kinase (CDK) inhibitor.